-- The FDA has accepted an IND application supporting clinical development of ANG-3070 in IPF -- Phase 1b trial to be initiated to gather tolerability, safety, and pharmacokinetic data in IPF patients UNIONDALE, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced U.S. Food and Drug ...
